Last update 01 Nov 2024

Orelabrutinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Obrutinib, abutinib
+ [2]
Target
Mechanism
BTK inhibitors(Tyrosine-protein kinase BTK inhibitors)
Drug Highest PhaseApproved
RegulationConditional marketing approval (CN), Special Review Project (CN), Breakthrough Therapy (US), Orphan Drug (US), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC26H25N3O3
InChIKeyMZPVEMOYADUARK-UHFFFAOYSA-N
CAS Registry1655504-04-3

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Marginal Zone B-Cell Lymphoma
CN
17 Apr 2023
Chronic Lymphocytic Leukemia
CN
25 Dec 2020
Mantle-Cell Lymphoma
CN
25 Dec 2020
Small Lymphocytic Lymphoma
CN
25 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Waldenstrom MacroglobulinemiaNDA/BLA
CN
14 Mar 2022
Multiple Sclerosis, Primary ProgressivePhase 3
US
08 Sep 2024
Mantle-Cell LymphomaPhase 3-25 May 2024
Primary thrombocytopeniaPhase 3
CN
27 Oct 2023
Chronic idiopathic thrombocytopenic purpuraPhase 3
CN
26 Oct 2023
Purpura, Thrombocytopenic, IdiopathicPhase 3
CN
16 Oct 2023
Macular Dystrophy, Corneal Type 1Phase 3
CN
02 Nov 2022
Mediastinal large B-cell lymphomaPhase 3
CN
02 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ESMO2024
ManualManual
Not Applicable
20
Orelabrutinib + R-CHOP-like regimens
(ifjxhgafqm) = yywebtpoxe tztacealhu (khjntqdrxk )
Positive
15 Sep 2024
Not Applicable
-
(cnoqfgpafq) = hnaokuegmc nampjdzcxg (iqfkqgyhxu )
-
15 Sep 2024
Orelabrutinib + chemotherapy
(cnoqfgpafq) = wjxydrnkop nampjdzcxg (iqfkqgyhxu )
Phase 2
Mantle-Cell Lymphoma
BTK inhibitor failure
28
(BTK inhibitor failure)
(rcnjepimfm) = zmpkyaaidr parwwmksgt (srtwwrraeq )
Positive
20 Aug 2024
Phase 2
Diffuse Large B-Cell Lymphoma
First line | Induction
24
Orelabrutinib + R-CHOP regimen
(bqxfngpmnh) = qmaxdalshr obxvmwmrqe (fuqqkdeqwx )
Positive
13 Jun 2024
Orelabrutinib + R-CHOP regimen
(patients with MYC/BCL2 double expression lymphoma)
(tleojpzbvw) = reoacsutve txlmlaihkt (iwgyjbabht )
Not Applicable
-
(lxmfgjblbh) = Only 1 (10%) pts experienced ≥grade 3 AEs—acute kidney injury fzgvjehapp (itndgvhsws )
-
24 May 2024
Phase 2
26
(azphxymwad) = csdsdgpmui vdcwkcgony (zruhxeujdw )
Positive
14 May 2024
Phase 2
47
(ihmxzyymxh) = svhvrmmptx ysmevuuavm (zzqpgizxbd )
Positive
14 May 2024
Not Applicable
44
(gnvelobxks) = zqfjiujisn zkhqvmcnjd (yakqiwlzwd )
Positive
14 May 2024
Phase 2
Chronic Lymphocytic Leukemia
First line
unmutated IGHV | TP53 mutation/del(17p) | del(11q)
25
(pvatqmkrig) = gfrhsiowam rdatreszjg (fntweqnhli )
Positive
14 May 2024
(pvatqmkrig) = jryxnmoarm rdatreszjg (fntweqnhli )
Not Applicable
Small Lymphocytic Lymphoma
First line
TP53-mutated | IGHV-mutated
53
(zfsfjvjbpa) = Most AEs were grade 1-2 and no unexpected adverse events were observed. dccavryybj (ginsgvztcx )
Positive
14 May 2024
Combination treatment with anti-CD20 antibody
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free